12-hydroxy-5-8-10-14-eicosatetraenoic-acid and arachidonyltrifluoromethane

12-hydroxy-5-8-10-14-eicosatetraenoic-acid has been researched along with arachidonyltrifluoromethane* in 2 studies

Other Studies

2 other study(ies) available for 12-hydroxy-5-8-10-14-eicosatetraenoic-acid and arachidonyltrifluoromethane

ArticleYear
Eicosanoid metabolism in human platelets is modified by albumin.
    Advances in experimental medicine and biology, 1999, Volume: 469

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Arachidonate 12-Lipoxygenase; Arachidonic Acid; Arachidonic Acids; Binding, Competitive; Blood Platelets; Eicosanoids; Enzyme Inhibitors; Estrenes; Humans; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Kinetics; Lipoxygenase Inhibitors; Phospholipases A; Platelet Activation; Pyrrolidinones; Serum Albumin; Type C Phospholipases

1999
Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets.
    The Journal of biological chemistry, 1994, Jun-03, Volume: 269, Issue:22

    Arachidonyl trifluoromethyl ketone (AACOCF3) is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2) (Street, I. P., Lin, H.-K., Laliberté, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). AACOCF3 and a number of its structural analogues have been used to investigate the role of cPLA2 in the cellular generation of free arachidonic acid (AA) and in eicosanoid biosynthesis. AACOCF3 inhibited the release of AA from calcium ionophore-challenged U937 cells (IC50 = 8 microM, 2 x 10(6) cells ml-1) and from platelets (IC50 = 2 microM, 4 x 10(7) cells ml-1). Arachidonyl methyl ketone (AACOCH3) and AACH(OH)CF3, both of which are noninhibitory to the purified cPLA2, did not inhibit the production of AA in the ionophore-challenged cells. In addition to the release of AA, AACOCF3 also inhibited the production of 12-hydroxyeicosatetraenoic acid (12-HETE) and thromboxane B2, two of the major metabolites of AA produced by platelets. The inhibition of 12-HETE biosynthesis showed a dose dependence similar to that of AA release in ionophore-challenged platelets; however, when platelet 12-HETE production was stimulated with 10 microM AA to circumvent the PLA2-dependent step, AACOCF3 no longer inhibited the production of 12-HETE. In contrast, AACOCF3 blocked thromboxane B2 formation by both calcium ionophore- and AA-challenged platelets, indicating that the compound affects the cyclooxygenase pathway in addition to AA release. The crude cytosol and membrane fractions from platelets were assayed for calcium-dependent and calcium-independent PLA2 activities and for the susceptibility of each to inhibition by AACOCF3. At AACOCF3 concentrations as high as 10 mol %, only one of the observed PLA2 activities was inhibited by more than 25%. The AACOCF3-susceptible PLA2 (77% inhibition at 1.6 mol %) was found in the cytosolic platelet fraction and showed the functional characteristics of the cPLA2. These results suggest that the cPLA2 plays an important role in the generation of free AA for 12-HETE biosynthesis in platelets.

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Calcimycin; Calcium; Cell Line; Cell Membrane; Cytosol; Humans; Hydroxyeicosatetraenoic Acids; Kinetics; Molecular Weight; Phospholipases A; Phospholipases A2; Thromboxane B2

1994